TipRanks
GT Biopharma (DE:OXI)
FRANKFURT:OXI
Germany Market
OXI
GT Biopharma
RESEARCH TOOLSreports

GT Biopharma (OXI) Income Statement

0 Followers

GT Biopharma Income Statement

Last quarter (Q2 2026), GT Biopharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, GT Biopharma's net income was $-4.52M. See GT Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 12.42M$ 14.36M$ 13.58M$ 21.26M$ 57.52M
Depreciation and Amortization
$ 0.00$ 0.00$ 13.58M$ 0.00$ 0.00
EBITDA
$ -28.23M$ -13.16M$ 5.98M$ -20.96M$ -57.48M
Operating Income
$ -12.42M$ -14.36M$ -13.58M$ -21.26M$ -57.52M
Other Income/Expenses
$ -15.93M$ 1.20M$ 5.98M$ 373.00K$ -498.00K
Pretax Income
$ -28.35M$ -13.16M$ -7.60M$ -20.88M$ -58.01M
Net Income
$ -28.35M$ -13.16M$ -7.60M$ -20.88M$ -58.01M
Per Share Metrics
Basic EPS
$ -156.25$ -173.50$ -141.00$ -16.50$ -51.50
Diluted EPS
$ -156.25$ -173.50$ -141.00$ -16.50$ -51.50
Weighted Average Shares Outstanding
 220.53K 75.88K 53.88K 1.27M 1.13M
Weighted Average Shares Outstanding (Diluted)
 220.53K 75.88K 53.92K 1.27M 1.13M
Currency in USD

GT Biopharma Earnings and Revenue History